Linagliptin-Metformin Stada

Linagliptin and Metformin Hydrochloride, the active ingredient in Linagliptin-Metformin Stada, is a DPP‑4 inhibitor and biguanide presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control.

GNH USA supplies Linagliptin-Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin-Metformin Stada is used in the management of type 2 diabetes, targeting hyperglycaemia through combined mechanisms.

Type 2 diabetes mellitus: improves glycaemic control when added to diet and exercise. Adjunct to metformin therapy: provides additional DPP‑4 inhibition for patients inadequately controlled on metformin alone. Combination with other oral antidiabetics: used alongside sulfonylureas or SGLT2 inhibitors to achieve target HbA1c levels.

The combination may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Upper respiratory symptoms: nasopharyngitis or sinus congestion.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypersensitivity: skin rash, angioedema, or anaphylactic reactions. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.

Before prescribing Linagliptin-Metformin Stada, clinicians should consider several safety aspects.

Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter. Hepatic function monitoring: avoid use in patients with severe liver disease. Lactic acidosis risk: contraindicated in patients with conditions predisposing to hypoxia or severe infection. Heart failure status: use with caution in patients with NYHA class III/IV heart failure. Concomitant medication review: assess for drugs that may affect renal clearance or increase hypoglycaemia risk. Store at room temperature: keep in the original container, protect from moisture and heat.

Linagliptin-Metformin Stada can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing metformin accumulation risk. - Cimetidine: can raise linagliptin plasma concentrations, enhancing potential side effects. - Strong CYP3A4 inhibitors: may increase linagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics and ACE inhibitors: may affect renal function, requiring dose adjustment of metformin. - Other antidiabetic agents: combined use can increase risk of hypoglycaemia. - Alcohol: can potentiate metformin‑related lactic acidosis.